Please provide your email address to receive an email when new articles are posted on . Chronic myeloid leukemia is a hematologic stem-cell disorder characterized by excessive proliferation and ...

Nilotinib (Tasigna®) is a highly potent and selective inhibitor of breakpoint cluster region (BCR)–V-abl Abelson murine leukemia viral oncogene homolog 1 (ABL1), which was rationally designed based on ...

A Georgetown University Medical Center clinical trial investigating the cancer drug nilotinib in people with Alzheimer's disease finds that it is safe and well-tolerated, and researchers say the drug ...

Adults with Ph+ CML in the CP or AP, who had imatinib resistance or intolerance and had also failed to respond to dasatinib therapy, received oral nilotinib at a starting dose of 400 mg twice daily on ...

Patients with chronic myeloid leukemia (CML) who have a sustained deep molecular response can maintain treatment-free remission for at least 48 weeks after using second-line nilotinib, according to a ...

WASHINGTON - A Georgetown University Medical Center clinical trial investigating the cancer drug nilotinib in people with Alzheimer's disease finds that it is safe and well-tolerated, and researchers ...

You have full access to this article via your institution. In agreement with these data, Davies et al. also did not see a significant reduction of TEA levels at the 2-h time point in the presence of ...

The chronic myeloid leukemia drug nilotinib (Tasigna) improved biomarkers and cognitive outcomes in people with dementia with Lewy bodies (DLB), a small phase II trial showed. In a study of 43 DLB ...

Although most patients with chronic myeloid leukemia (CML) in chronic phase respond well to front-line therapy with imatinib, some patients do not achieve the desirable end point, and others may ...

CHICAGO (December 5, 2019) -- Northwestern University and the Parkinson Study Group announced that the Nilotinib in Parkinson's Disease (NILO-PD) study showed that nilotinib, an FDA-approved treatment ...

How to follow-up advanced-stage serous borderline tumors of the ovary: Analysis of the mode of diagnosis of recurrence in patients with stage II-III disease. Background: Nilotinib, a multi-target ...